Alloreactive natural killer cells have been emerging as potent effector cells against acute myeloid leukemia. Several biological and immunologic issues still require full elucidation. The impact of donor natural killer alloreactivity is an important issue. Future trials on natural killer cells should correlate clinical results with donor alloreactive natural killer cell repertoire.